Vaxcyte has patented methods for producing immunogenic compositions with non-natural amino acids for efficient antigen presentation. The patent includes a carrier protein with specific non-natural amino acids for crosslinked protein-antigen conjugate vaccines. This technology allows for potent antigen presentation and simplified purification. GlobalData’s report on Vaxcyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Vaxcyte, LPS antibody-based anti-bacterials was a key innovation area identified from patents. Vaxcyte's grant share as of April 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.
Immunogenic compositions containing non-natural amino acids for vaccines
The granted patent (Publication Number: US11951165B2) discloses a carrier protein designed for use in a crosslinked protein-antigen conjugate vaccine. The carrier protein must have a minimum of 98% sequence identity to specific sequences (SEQ ID NO:9 and SEQ ID NO:14) outlined in the claims. Additionally, the carrier protein must contain a 2-amino-3-(4-(azidomethyl)phenyl)propanoic acid (pAMF) non-natural amino acid (nnAA) at specific residue positions (34, 213, 245, 265, 386, and 527) as per the mentioned sequences.
Furthermore, the carrier protein should not include an Arg-Arg dipeptide, as specified in one of the claims. The carrier protein described in the patent claims aims to enhance the efficacy of crosslinked protein-antigen conjugate vaccines by utilizing specific sequences and non-natural amino acids. This innovation in carrier protein design could potentially lead to the development of more effective vaccines with improved immunogenicity and targeted antigen delivery, contributing to advancements in the field of vaccine development and immunization strategies.
To know more about GlobalData’s detailed insights on Vaxcyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
